Insider Trading History of Qvt Fund V Lp

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) by Qvt Fund V Lp since 2013. The trader's CIK number is 1543904. At the time of the last reporting, Qvt Fund V Lp was the 10% Owner of Myovant Sciences Ltd.. (stock ticker symbol MYOV). Also see all insider trading activities at Myovant Sciences Ltd..

Note that in the past QVT Fund V LP also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Axovant Gene Therapies Ltd. (AXON) by Qvt Fund V Lp

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2018 AXON 14,285,714 $24,999,999 0 $0 0 $0

Yearly summary of insider trading at Achillion Pharmaceuticals Inc (ACHN) by Qvt Fund V Lp

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2013 ACHN 3,500,000 $22,227,139 2,754,900 $9,366,660 0 $0

Yearly summary of insider trading at Urovant Sciences Ltd. (UROV) by Qvt Fund V Lp

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2018 UROV 2,678,571 $37,499,994 0 $0 0 $0

Yearly summary of insider trading at Myovant Sciences Ltd. (MYOV) by Qvt Fund V Lp

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2019 MYOV 2,424,242 $19,999,996 0 $0 0 $0
2018 MYOV 1,110,015 $22,500,004 0 $0 0 $0

Yearly summary of insider trading at Concert Pharmaceuticals, Inc. (CNCE) by Qvt Fund V Lp

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2014 CNCE 300,000 $4,200,000 0 $0 0 $0

Yearly summary of insider trading at Agenus Inc (AGEN) by Qvt Fund V Lp

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2015 AGEN 0 $0 2,343,630 $12,557,169 0 $0


Insider trading activities at 6 companies by Qvt Fund V Lp:

1. Axovant Gene Therapies Ltd. (AXON)

2. Achillion Pharmaceuticals Inc (ACHN)

3. Urovant Sciences Ltd. (UROV)

4. Myovant Sciences Ltd. (MYOV)

5. Concert Pharmaceuticals, Inc. (CNCE)

6. Agenus Inc (AGEN)

Table 1. Insider trading of Axovant Gene Therapies Ltd. (AXON) by Qvt Fund V Lp

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2018-06-05 AXON Buy 14,285,714 1.75 24,999,999

Table 2. Insider trading of Achillion Pharmaceuticals Inc (ACHN) by Qvt Fund V Lp

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2013-09-30 ACHN Sale 2,754,900 3.40 9,366,660
2013-08-08 ACHN Buy 36,300 6.48 235,224
2013-08-09 ACHN Buy 65,982 6.37 420,305
2013-07-11 ACHN Buy 401,017 6.46 2,592,574
2013-07-09 ACHN Buy 200,000 6.30 1,260,000
2013-07-10 ACHN Buy 190,944 6.37 1,215,358
2013-07-05 ACHN Buy 197,300 6.24 1,230,165
2013-07-08 ACHN Buy 445,209 6.30 2,804,816
2013-07-02 ACHN Buy 1,500,000 6.37 9,559,500
2013-07-03 ACHN Buy 463,248 6.28 2,909,197

Table 3. Insider trading of Urovant Sciences Ltd. (UROV) by Qvt Fund V Lp

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2018-10-01 UROV Buy 2,678,571 14.00 37,499,994

Table 4. Insider trading of Myovant Sciences Ltd. (MYOV) by Qvt Fund V Lp

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2019-06-04 MYOV Buy 2,424,242 8.25 19,999,996
2018-04-02 MYOV Buy 1,110,015 20.27 22,500,004

Table 5. Insider trading of Concert Pharmaceuticals, Inc. (CNCE) by Qvt Fund V Lp

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2014-02-19 CNCE Buy 300,000 14.00 4,200,000

Table 6. Insider trading of Agenus Inc (AGEN) by Qvt Fund V Lp

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2015-01-09 AGEN Sale 2,343,630 5.36 12,557,169

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Qvt Fund V Lp (10% Owner of Myovant Sciences Ltd. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.